Navigation Links
Heart Failure Drug May Help More in Higher Doses

Study finds increase lowers chance of hospitalization or death

TUESDAY, Nov. 17 (HealthDay News) -- For people with heart failure, high doses of the drug losartan, an angiotensin-receptor blocker (ARB), reduce the risk for hospital admission and death, a new study shows.

Though ARBs are known to benefit people with heart failure, the study focused on whether dose level makes a difference. The findings were to be presented during the American Heart Association's annual meeting, Nov. 14 to 18, in Orlando, Fla., and were published online Nov. 17 in The Lancet.

The study included 3,846 people in 30 countries who had heart failure, a left-ventricular ejection fraction of 40 percent or less and intolerance to angiotensin-converting-enzyme (ACE) inhibitors. The participants were randomly assigned to take 50 or 150 milligrams a day of losartan (Cozaar).

After a median follow-up of 4.7 years, 43 percent of those in the high-dose group and 46 percent of those in the lower-dose group had died or were admitted to hospital for heart failure.

Overall, the higher dose of losartan reduced the risk for death or admission for heart failure by 10 percent, according to the study. When looked at separately, the risk for death was 6 percent lower for the high-dose group, and the risk for hospital admission for heart failure was 13 percent lower.

Kidney impairment, low blood pressure and hyperkalemia (high levels of blood potassium that can cause potentially fatal abnormal heart rhythm) were more common in the high-dose group, the study reported.

"These findings suggest that increased doses of an ARB are needed to achieve the maximum benefit for clinical outcomes and symptoms related to heart failure in this population," wrote Dr. Marvin A. Konstam, a cardiologist at Tufts Medical Center and Tufts University School of Medicine in Boston, and his fellow researchers.

More information

The U.S. National Heart, Lung, and Blood Institute has more about heart failure.

-- Robert Preidt

SOURCE: The Lancet, news release, Nov. 17, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New Heart Attack Treatment Guidelines Stress Coordination
2. Terumo Heart, Inc. Wins Top Healthcare Category Honors at's 5th Annual ‘Deals Of The Year' Award Ceremony
3. Study Reveals Evidence of Heart Disease in Ancient Egyptian Mummies
4. American College of Cardiology/American Heart Association Comment on the FDA Public Health Advisory Regarding a Drug Interaction Between Clopidogrel and Omeprazole
5. Your own stem cells can treat heart disease
6. Obesity Rolling Back Gains in Heart Health
7. The Mummies Curse: Heart Disease
8. Heartburn Drugs Can Thwart Popular Blood Thinner
9. Highlights of NHLBI-supported research presented at American Heart Associations Scientific Sessions
10. Newer heart devices significantly improve survival, complication rate and quality of life
11. Pitt part of $100 million NHLBI Bench to Bassinet effort in congenital heart disease
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... by the University of Toronto and the University of British Columbia suggested that laws ... head injuries. The article explains that part of the reason for the controversial conclusion ...
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A simply groundbreaking ... is an interesting show that delves into an array of issues that are presently ... could benefit from open dialogue, this show is changing the subjects consumers focus on, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... --> --> ... find optimal contrast weighting of MRI for patients with ... a research agreement with SyntheticMR in order to use SyMRI ... is possible to generate multiple contrast images from a single ... left, thus making it possible to both fine tune images ...
Breaking Medicine Technology: